Literature DB >> 20937460

Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role.

Carolina M Bolino1, Premysl Bercik.   

Abstract

Irritable bowel syndrome (IBS) is a symptom complex characterized by recurrent abdominal pain or discomfort, and accompanied by abnormal bowel habits, in the absence of any discernible organic abnormality. Its origin remains unclear, partly because multiple pathophysiologic mechanisms are likely to be involved. A significant proportion of patients develop IBS symptoms after an episode of gastrointestinal infection. In addition to gastrointestinal pathogens, recent evidence suggests that patients with IBS have abnormal composition and higher temporal instability of their intestinal microbiota. Because the intestinal microbiota is an important determinant of normal gut function and immunity, this instability may constitute an additional mechanism that leads to symptom generation and IBS. More importantly, a role for altered microbiota composition in IBS raises the possibility of therapeutic interventions through selective antibiotic or probiotic administration. The new concept of functional bowel diseases incorporates the bidirectional communication between the gut and the central nervous system (gut-brain axis), which may explain the multiple facets of IBS by linking emotional and cognitive centers of the brain with peripheral functioning of the gastrointestinal tract and vice versa.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20937460     DOI: 10.1016/j.idc.2010.07.005

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  7 in total

1.  Research on Correlation Between Psychological Factors, Mast Cells, and PAR-2 Signal Pathway in Irritable Bowel syndrome.

Authors:  Guanqun Chao; Zhaojun Wang; Shuo Zhang
Journal:  J Inflamm Res       Date:  2021-04-14

2.  Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model.

Authors:  Rebeca Martín; Sylvie Miquel; Florian Chain; Jane M Natividad; Jennifer Jury; Jun Lu; Harry Sokol; Vassilia Theodorou; Premysl Bercik; Elena F Verdu; Philippe Langella; Luis G Bermúdez-Humarán
Journal:  BMC Microbiol       Date:  2015-03-21       Impact factor: 3.605

Review 3.  The relationship between intestinal parasites and some immune-mediated intestinal conditions.

Authors:  Rasoul Mohammadi; Ahmad Hosseini-Safa; Mohammad Javad Ehsani Ardakani; Mohammad Rostami-Nejad
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015

Review 4.  Profile of rifaximin and its potential in the treatment of irritable bowel syndrome.

Authors:  Natalya Iorio; Zubair Malik; Ron Schey
Journal:  Clin Exp Gastroenterol       Date:  2015-06-08

5.  A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.

Authors:  Shamsuddin M Ishaque; S M Khosruzzaman; Dewan Saifuddin Ahmed; Mukesh Prasad Sah
Journal:  BMC Gastroenterol       Date:  2018-05-25       Impact factor: 3.067

Review 6.  Dietary Triggers in Irritable Bowel Syndrome: Is There a Role for Gluten?

Authors:  Umberto Volta; Maria Ines Pinto-Sanchez; Elisa Boschetti; Giacomo Caio; Roberto De Giorgio; Elena F Verdu
Journal:  J Neurogastroenterol Motil       Date:  2016-10-30       Impact factor: 4.924

7.  Therapeutic Effects of Low-dose Bismuth Subcitrate on Symptoms and Health-related Quality of Life in Adult Patients with Irritable Bowel Syndrome: A Clinical Trial.

Authors:  Hamed Daghaghzadeh; Ardalan Memar; Yasaman Mohamadi; Nooshin Rezakhani; Parastoo Safazadeh; Sarina Aghaha; Payman Adibi
Journal:  J Res Pharm Pract       Date:  2018 Jan-Mar
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.